
EyePoint, Inc.: shareholders and insiders
Price
$0.26
November 19, 2026Market cap $30M
What Ploutos Investor adds for EyePoint
Part of Ploutos Investor, €9.99 a month
- The full history: 16 fiscal years, from FY2010
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Nov 20, 2025 to Aug 24, 2026, from their own Form 4 filings.
Bought on the market
$72.0K
2 people
Sold on the market
$2.0M
3 people
From Nov 20, 2025 to Nov 20, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan53%
- The rest47%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 20, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·bought $72.0K by 2 people·sold $917.4K by 1 person
- 2025: no buys, sold $1.1M by 2 people
- 2026: bought $72.0K by 2 people, sold $917.4K by 1 person
- Aug 20, 2026George ElstonChief Financial OfficerKind
- Aug 20, 2026George ElstonChief Financial OfficerKind
- Aug 20, 2026George ElstonChief Financial OfficerKind
- Aug 20, 2026George ElstonChief Financial OfficerKind
- Aug 18, 2026Karen L. ZaderejDirectorKind
- Jul 10, 2026Jay S. DukerPresident and CEOKind
- Jul 10, 2026Jay S. DukerPresident and CEOKind
- Jun 30, 2026Ramiro RibeiroChief Medical OfficerKind10b5-1
- Jun 30, 2026Ramiro RibeiroChief Medical OfficerKind10b5-1
- Jun 30, 2026Ramiro RibeiroChief Medical OfficerKind10b5-1
- Jun 30, 2026Ramiro RibeiroChief Medical OfficerKind10b5-1
- May 25, 2026George ElstonChief Financial OfficerKind
- May 25, 2026George ElstonChief Financial OfficerKind
- Apr 17, 2026Ramiro RibeiroChief Medical OfficerKind10b5-1
- Mar 16, 2026Jay S. DukerPresident and CEOKind
- Mar 4, 2026Ramiro RibeiroChief Medical OfficerKind10b5-1
- Feb 17, 2026Ramiro RibeiroChief Medical OfficerKind10b5-1
- Jan 5, 2026Ramiro RibeiroChief Medical OfficerKind10b5-1
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 20, 2026 | George ElstonChief Financial Officer | 5,000 | – | – | Form 4 | |
| Aug 20, 2026 | George ElstonChief Financial Officer | 5,000 | – | – | Form 4 | |
| Aug 20, 2026 | George ElstonChief Financial Officer | 65.0K | – | – | Form 4 | |
| Aug 20, 2026 | George ElstonChief Financial Officer | 65.0K | – | – | Form 4 | |
| Aug 18, 2026 | Karen L. ZaderejDirector | 10.6K | $4.93 | $52.3K | Form 4 | |
| Jul 10, 2026 | Jay S. DukerPresident and CEO | 16.7K | – | – | Form 4 | |
| Jul 10, 2026 | Jay S. DukerPresident and CEO | 8,059 | $14.72 | $118.6K | Form 4 | |
| Jun 30, 2026 | Ramiro RibeiroChief Medical Officer | 10b5-1 | 2,437 | $8.26 | $20.1K | Form 4 |
| Jun 30, 2026 | Ramiro RibeiroChief Medical Officer | 10b5-1 | 2,438 | $8.26 | $20.1K | Form 4 |
| Jun 30, 2026 | Ramiro RibeiroChief Medical Officer | 10b5-1 | 2,437 | $15.00 | $36.6K | Form 4 |
| Jun 30, 2026 | Ramiro RibeiroChief Medical Officer | 10b5-1 | 2,438 | $15.02 | $36.6K | Form 4 |
| May 25, 2026 | George ElstonChief Financial Officer | 7,500 | – | – | Form 4 | |
| May 25, 2026 | George ElstonChief Financial Officer | 3,627 | $12.93 | $46.9K | Form 4 | |
| Apr 17, 2026 | Ramiro RibeiroChief Medical Officer | 10b5-1 | 2,437 | $15.00 | $36.6K | Form 4 |
| Mar 16, 2026 | Jay S. DukerPresident and CEO | 1,500 | $13.15 | $19.7K | Form 4 | |
| Mar 4, 2026 | Ramiro RibeiroChief Medical Officer | 10b5-1 | 2,438 | $17.87 | $43.6K | Form 4 |
| Feb 17, 2026 | Ramiro RibeiroChief Medical Officer | 10b5-1 | 2,437 | $15.00 | $36.6K | Form 4 |
| Jan 5, 2026 | Ramiro RibeiroChief Medical Officer | 10b5-1 | 42.5K | $17.10 | $727.5K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before May 27, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by EYPT's officers and directors from 2012 up to November 19, 2025, 14 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 9 more, back to 2012
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- JANUS HENDERSON GROUP Ltd.Share of class10.9%
- Tang Capital Managementwith 5 more personsShare of class9.60%
- Cormorant Asset Management, LPwith 1 more personShare of class8.35%
- BlackRock, Inc.Share of class7.70%
- Franklin Resources, Inc.with 3 more personsShare of class6.10%
- Adage Capital Management, L.P.with 2 more personsShare of class5.71%
- Commodore Capital LPwith 3 more personsShare of class5.10%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| JANUS HENDERSON GROUP Ltd. | 10.9% | 9.37M | Sep 8, 2026 | 13G | |
| Tang Capital Managementwith 5 more persons | 9.60% | 8.25M | Oct 27, 2026 | 13G | |
| Cormorant Asset Management, LPwith 1 more person | 8.35% | 7.00M | Aug 14, 20262 filings since Dec 8, 2025 | 13G/A | |
| BlackRock, Inc. | 7.70% | 6.43M | Jul 28, 20262 filings since Oct 17, 2025 | 13G/A | |
| Franklin Resources, Inc.with 3 more persons | 6.10% | 4.14M | Jan 27, 20252 filings since Oct 31, 2024 | 13G/A | |
| Adage Capital Management, L.P.with 2 more persons | 5.71% | 4.79M | Aug 12, 20266 filings since Feb 12, 2025 | 13G | |
| Commodore Capital LPwith 3 more persons | 5.10% | 4.25M | Jun 3, 2026 | 13G |
Fell to 5% or less (6)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Point72 (Cohen)In the quarter
- Citadel Advisors (Griffin)In the quarter+1.0%
- Millennium Mgmt (Englander)In the quarter+314%
- D.E. ShawIn the quarter
- AQR CapitalIn the quarter
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Point72 (Cohen) | – | – | 0.00% | |
| Citadel Advisors (Griffin) | 2.00M | +1.0% | $6.5M | 0.00% |
| Millennium Mgmt (Englander) | 2.07M | +314% | $6.8M | 0.00% |
| D.E. Shaw | 1.04M | $3.4M | 0.00% | |
| AQR Capital | 314.0K | $1.0M | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 18.7% of its shares outstanding were held short, +2.3% since the report before.
- Shares held short
- 21.26M
- 18.7%
- Since the report before20.79M on Sep 30, 2026
- +2.3%
- 8.1
- 2.63M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 84%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 5.35M
- Nov 15, 2023: Shares held short 5.44M
- Nov 30, 2023: Shares held short 7.01M
- Dec 15, 2023: Shares held short 4.75M
- Dec 29, 2023: Shares held short 5.33M
- Jan 12, 2024: Shares held short 5.20M
- Jan 31, 2024: Shares held short 5.14M
- Feb 15, 2024: Shares held short 4.75M
- Feb 29, 2024: Shares held short 5.72M
- Mar 15, 2024: Shares held short 6.58M
- Mar 28, 2024: Shares held short 6.85M
- Apr 15, 2024: Shares held short 6.54M
- Apr 30, 2024: Shares held short 6.60M
- May 15, 2024: Shares held short 8.13M
- May 31, 2024: Shares held short 7.74M
- Jun 14, 2024: Shares held short 8.98M
- Jun 28, 2024: Shares held short 9.63M
- Jul 15, 2024: Shares held short 10.08M
- Jul 31, 2024: Shares held short 9.55M
- Aug 15, 2024: Shares held short 9.48M
- Aug 30, 2024: Shares held short 9.11M
- Sep 13, 2024: Shares held short 9.10M
- Sep 30, 2024: Shares held short 8.93M
- Oct 15, 2024: Shares held short 9.17M
- Oct 31, 2024: Shares held short 9.68M
- Nov 15, 2024: Shares held short 9.88M
- Nov 29, 2024: Shares held short 9.25M
- Dec 13, 2024: Shares held short 9.41M
- Dec 31, 2024: Shares held short 10.34M
- Jan 15, 2025: Shares held short 10.58M
- Jan 31, 2025: Shares held short 10.72M
- Feb 14, 2025: Shares held short 11.09M
- Feb 28, 2025: Shares held short 10.73M
- Mar 14, 2025: Shares held short 10.83M
- Mar 31, 2025: Shares held short 10.93M
- Apr 15, 2025: Shares held short 11.82M
- Apr 30, 2025: Shares held short 10.07M
- May 15, 2025: Shares held short 7.21M
- May 30, 2025: Shares held short 7.17M
- Jun 13, 2025: Shares held short 6.74M
- Jun 30, 2025: Shares held short 6.93M
- Jul 15, 2025: Shares held short 6.72M
- Jul 31, 2025: Shares held short 6.91M
- Aug 15, 2025: Shares held short 7.69M
- Aug 29, 2025: Shares held short 8.45M
- Sep 15, 2025: Shares held short 8.89M
- Sep 30, 2025: Shares held short 8.00M
- Oct 15, 2025: Shares held short 8.13M
- Oct 31, 2025: Shares held short 7.56M
- Nov 14, 2025: Shares held short 8.63M
- Nov 28, 2025: Shares held short 7.88M
- Dec 15, 2025: Shares held short 7.31M
- Dec 31, 2025: Shares held short 8.63M
- Jan 15, 2026: Shares held short 8.27M
- Jan 30, 2026: Shares held short 8.64M
- Feb 13, 2026: Shares held short 9.53M
- Feb 27, 2026: Shares held short 10.87M
- Mar 13, 2026: Shares held short 12.48M
- Mar 31, 2026: Shares held short 13.39M
- Apr 15, 2026: Shares held short 13.66M
- Apr 30, 2026: Shares held short 14.19M
- May 15, 2026: Shares held short 14.15M
- May 29, 2026: Shares held short 15.10M
- Jun 15, 2026: Shares held short 15.08M
- Jun 30, 2026: Shares held short 15.11M
- Jul 15, 2026: Shares held short 16.43M
- Jul 31, 2026: Shares held short 18.02M
- Aug 14, 2026: Shares held short 18.43M
- Aug 31, 2026: Shares held short 18.11M
- Sep 15, 2026: Shares held short 19.81M
- Sep 30, 2026: Shares held short 20.79M
- Oct 15, 2026: Shares held short 21.26M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading59.1% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 59.1% of the shares in the reported trades were short sales, against 58.6% in the 14 before.
- Last 14 sessionsNov 2, 2026 – Nov 19, 2026
- 59.1%
- The 14 beforeOct 13, 2026 – Oct 30, 2026
- 58.6%
- Change
- +0.5 pts
- Short sales a dayon average, of 2.17M shares
- 1.28M
- More than atof 3,666 US-listed companies, same days
- 80%
- Median of alleight in ten from 34.5% to 63.8%
- 50.4%
- Short sales
- Oct 13, 2026: Short sales 57%
- Oct 14, 2026: Short sales 56.9%
- Oct 15, 2026: Short sales 45.6%
- Oct 16, 2026: Short sales 61.1%
- Oct 19, 2026: Short sales 61.5%
- Oct 20, 2026: Short sales 51.9%
- Oct 21, 2026: Short sales 49.5%
- Oct 22, 2026: Short sales 53.6%
- Oct 23, 2026: Short sales 73.1%
- Oct 26, 2026: Short sales 65%
- Oct 27, 2026: Short sales 60.8%
- Oct 28, 2026: Short sales 45.7%
- Oct 29, 2026: Short sales 60%
- Oct 30, 2026: Short sales 69.6%
- Nov 2, 2026: Short sales 53.2%
- Nov 3, 2026: Short sales 45.9%
- Nov 4, 2026: Short sales 72%
- Nov 5, 2026: Short sales 65.5%
- Nov 6, 2026: Short sales 57.4%
- Nov 9, 2026: Short sales 38.1%
- Nov 10, 2026: Short sales 36.6%
- Nov 11, 2026: Short sales 75.7%
- Nov 12, 2026: Short sales 62.5%
- Nov 13, 2026: Short sales 55.4%
- Nov 16, 2026: Short sales 68.3%
- Nov 17, 2026: Short sales 57.9%
- Nov 18, 2026: Short sales 73.1%
- Nov 19, 2026: Short sales 74.7%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Cormorant Asset Management, LPOtherDirectly–
- Cormorant Global Healthcare Master Fund, LPTenPercentOwnerDirectly–
- Nancy LurkerDirectorDirectly206.5K
- Jay S. DukerPresident and CEODirectly86.4K
- George ElstonChief Financial OfficerDirectly122.5K
- Ye LiuDirectorDirectly–
- Therapeutics OcumensionDirectorDirectly100.2K
- Karen L. ZaderejDirectorDirectly49.1K
- David Scott JonesSVP & Chief Commercial OfficerDirectly38.0K
- Dario A. PaggiarinoChief Medical OfficerDirectly36.5K
- Goran AndoDirectorDirectly13.2K
- Wendy F DiciccoDirectorDirectly9,967
- Michael Craig PineChief Corp Dev.&Strat. OfficerDirectly5,343
- Ramiro RibeiroChief Medical OfficerDirectly2,438
- David R GuyerDirectorDirectly1,850
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Cormorant Asset Management, LPOther | – | 8.27M | Dec 4, 2025 | Form 4 |
| Cormorant Global Healthcare Master Fund, LPTenPercentOwner | – | 7.29M | Apr 18, 2024 | Form 4 |
| Nancy LurkerDirector | 206.5K | – | Dec 4, 2025 | Form 4 |
| Jay S. DukerPresident and CEO | 86.4K | 100.7K | Jul 10, 2026 | Form 4 |
| George ElstonChief Financial Officer | 122.5K | – | Aug 20, 2026 | Form 4 |
| Ye LiuDirector | – | 100.2K | Jan 11, 2024 | Form 4 |
| Therapeutics OcumensionDirector | 100.2K | – | Jan 11, 2024 | Form 4 |
| Karen L. ZaderejDirector | 49.1K | – | Aug 18, 2026 | Form 4 |
| David Scott JonesSVP & Chief Commercial Officer | 38.0K | – | Feb 2, 2024 | Form 4 |
| Dario A. PaggiarinoChief Medical Officer | 36.5K | – | Jan 26, 2024 | Form 4 |
| Goran AndoDirector | 13.2K | – | Aug 21, 2024 | Form 4 |
| Wendy F DiciccoDirector | 9,967 | – | Aug 20, 2024 | Form 4 |
| Michael Craig PineChief Corp Dev.&Strat. Officer | 5,343 | – | Dec 4, 2023 | Form 4 |
| Ramiro RibeiroChief Medical Officer | 2,438 | – | Jun 30, 2026 | Form 4 |
| David R GuyerDirector | 1,850 | – | Jul 12, 2024 | Form 4 |
A lower bound: it counts only the 15 officers and directors with a market trade since Nov 21, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IHEiShares U.S. Pharmaceuticals ETFWeight in the fund0.26%
- IWCiShares Micro-Cap ETFWeight in the fund0.24%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.06%
- IWMiShares Russell 2000 ETFWeight in the fund0.03%
- DFASDimensional U.S. Small Cap ETFWeight in the fund0.02%
- VXFVanguard Extended Market Index FundWeight in the fund0.01%
- IWNiShares Russell 2000 Value ETFWeight in the fund0.01%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.01%
- SCHASchwab U.S. Small-Cap ETFWeight in the fund0.01%
- VHTVanguard Health Care Index FundWeight in the fund0.00%
16 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 151
- Q4 2025: Managers 166
- Q1 2026: Managers 190
- Q2 2026: Managers 189
Institutional investors by quarter
The fund managers holding EYPT, quarter by quarter, from Q1 2018 to Q2 2025, 30 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 189 managers held 92.82M shares, worth $1.3B. During the quarter 25 opened a position, 26 closed one, 63 added and 60 trimmed.
The largest holders, Q2 2026
- Montanova CapitalIn the quarter
- BlackRockIn the quarter+4.0%
- Cormorant Asset ManagementIn the quarter-15%
- Federated HermesIn the quarter+0.2%
- Adage Capital Partners GpIn the quarter+46%
- Franklin ResourcesIn the quarter-4.8%
- Commodore CapitalIn the quarter+63%
- Jupiter TopcoIn the quarter
- Vanguard Capital ManagementIn the quarter+2.0%
- Paradigm Biocapital AdvisorsIn the quarter-8.0%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| Montanova Capital | 8.30M | $119M | |
| BlackRock | 7.46M | +4.0% | $107M |
| Cormorant Asset Management | 7.00M | -15% | $100M |
| Federated Hermes | 5.68M | +0.2% | $81M |
| Adage Capital Partners Gp | 4.83M | +46% | $69M |
| Franklin Resources | 4.81M | -4.8% | $69M |
| Commodore Capital | 4.60M | +63% | $66M |
| Jupiter Topco | 3.77M | $54M | |
| Vanguard Capital Management | 3.63M | +2.0% | $52M |
| Paradigm Biocapital Advisors | 2.89M | -8.0% | $41M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do EyePoint's filings show?
Who buys and sells is one part of EyePoint's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have EYPT's insiders bought or sold?
From May 27, 2026 to Aug 24, 2026 EyePoint's insiders bought $52.3K and sold $73.2K of shares on the market. 100% of the sales were under set 10b5-1 plans.
Which well-known managers hold EYPT?
5 of the managers we track held the shares on Sep 30, 2026. The largest position was Millennium Mgmt (Englander)'s, worth $6.8M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.